News Redesigned aminoglycoside may eliminate risk of hearing loss Researchers have diminished the toxicity of the aminoglycoside sisomicin — which can cause hearing damage or loss — by altering its molecular structure.…Published: 5 January 2015
News Interim results of stem cell treatment for multiple sclerosis show promise Stem cell treatment after high-dose immunosuppressive therapy could be an effective way to manage relapsing remitting multiple sclerosis.…Published: 31 December 2014
News Mistakes made by patients using medical devices points to need for better trainingA research team sought to identify the factors associated with incorrect use of metered-dose inhalers and epinephrine autoinjectors.…Published: 24 December 2014
News 2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …Published: 18 December 2014
News Risk of hyperglycaemia for diabetes patients using faulty insulin pensPeople with diabetes using insulin pens from a number of faulty batches manufactured by Owen Mumford are at risk of hyperglycaemia.…Published: 17 December 2014
News Initiative seeks to protect patients from acute kidney injury If you have not yet heard of sick day rules for reducing patients’ risk of acute kidney injury (AKI), you probably will soon.…Published: 16 December 2014
News Evidence still lacking for Ebola treatments, concludes European Medicines Agency Lack of evidence for seven investigational drugs being developed for the treatment of Ebola means it is impossible to make conclusions about their safety or efficacy.…Published: 16 December 2014
News Risk modelling study suggests aspirin’s harms outweigh benefits for younger women For most women, the long-term benefits of aspirin do not outweigh the increase in major gastrointestinal bleeding, say researchers.…Published: 15 December 2014
News Ebola clinical trial suspended after volunteers complain of joint pains A phase I clinical trial of the fast-tracked Ebola vaccine VSV-ZEBOV has been halted in Switzerland because some trial participants developed mild joint pain.…Published: 12 December 2014
News Chemoprevention with tamoxifen cuts risk of breast cancer by almost 30% Tamoxifen used in primary prevention cuts the risk of breast cancer by around 30% and this benefit lasts for at least 20 years, a long-term follow-up of the International Breast Cancer Intervention Study shows.…Published: 11 December 2014